UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 6, 2019
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in its charter)
Nevada | 001-37854 | 99-0367049 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices, including zip code)
(510) 984-1761
(Registrant’s telephone number, including area code)
Not Applicable
(Registrant’s former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.001 par value per share | EKSO | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On November 6, 2019, the compensation committee of the board of directors (the “Committee”) of Ekso Bionics Holdings, Inc. (the “Company”) approved certain grants of equity awards to the Company’s employees pursuant to the Company's Amended and Restated 2014 Stock Incentive Plan, including options to purchase the Company’s common stock granted to certain of the Company’s named executive officers (“NEO”) as listed below:
NEO | Number of Shares Underlying the Option |
Jack Peurach | 795,000 |
Jack Glenn | 240,000 |
Each option listed above becomes exercisable in 48 equal monthly installments starting on December 6, 2019.
All compensation for the NEOs for the fiscal year ended December 31, 2019, including the compensation disclosed above, will be reported by the Company in the Summary Compensation Table in the Company’s Annual Report on Form 10-K for the year ending December 31, 2019 or its proxy statement relating to the Company’s next annual meeting of stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2019.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
EKSO BIONICS HOLDINGS, INC. | ||||
By: | /s/ John F. Glenn | |||
Name: | John F. Glenn | |||
Title: | Chief Financial Officer |
Dated: November 12, 2019